Rothärmel M

Centre Hospitalier du Rouvray, Service Hospitalo-Universitaire de Psychiatrie, Centre d'Excellence Thérapeutique, Sotteville-lès-Rouen, France.

6 papers · ORCID

ArticleKetamine

Real-world clinical practice, effectiveness and safety of esketamine nasal spray in major depressive disorder patients: a French prospective cohort (ELLIPSE study).

Llorca PM, Sauvaget A, Olié E +12

Europe PMC2026
ArticleKetamine

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.

Rothärmel M, Mekaoui L, Kazour F +21

Europe PMC2026
ArticleKetamine

Effectiveness and factors associated with esketamine response during the 4-week induction period for treatment-resistant depression: post-hoc analysis of the real-world ESKALE study.

Samalin L, Rothärmel M, Mekaoui L +6

Europe PMC2026
ArticleKetamine

Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French Study.

Samalin L, Mekaoui L, Rothärmel M +5

Europe PMC2024
ArticleKetamine

Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray.

Samalin L, Mekaoui L, De Maricourt P +5

Europe PMC2024
ArticleKetamine

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France

Wattinne E, Mekaoui L, Rothärmel M +2

Europe PMC2021